BioHarvest Announces Appointment of Sharon Malka to Board of Directors
BioHarvest Sciences (NASDAQ: BHST) has appointed Sharon Malka as an independent director, effective immediately. Malka brings over 25 years of financial and capital markets experience to the board. He currently serves as CEO of Dotz Nano and is on the board of MediWound , where he previously held positions as CFO and CEO.
Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division, highlighted Malka's operational experience in advancing innovative technologies and structuring strategic transactions as valuable assets for the company's growth. Malka, a certified CPA with an MBA and Harvard Business School Executive Education, expressed enthusiasm about contributing to BioHarvest's development of science-based therapeutic solutions using its Botanical Synthesis technology.
BioHarvest Sciences (NASDAQ: BHST) ha nominato Sharon Malka come direttore indipendente, con effetto immediato. Malka porta al consiglio oltre 25 anni di esperienza nei settori finanziario e dei mercati dei capitali. Attualmente ricopre la carica di CEO di Dotz Nano ed è membro del consiglio di MediWound, dove in precedenza ha ricoperto le posizioni di CFO e CEO.
Il Dott. Zaki Rakib, Presidente del Consiglio e Presidente della Divisione Servizi CDMO di BioHarvest Sciences, ha evidenziato l'esperienza operativa di Malka nell'avanzamento di tecnologie innovative e nella strutturazione di transazioni strategiche come asset preziosi per la crescita dell'azienda. Malka, CPA certificato con un MBA e formazione esecutiva alla Harvard Business School, ha espresso entusiasmo nell'apportare il proprio contributo allo sviluppo di soluzioni terapeutiche basate sulla scienza da parte di BioHarvest, utilizzando la sua tecnologia di Sintesi Botanica.
BioHarvest Sciences (NASDAQ: BHST) ha nombrado a Sharon Malka como director independiente, con efecto inmediato. Malka aporta más de 25 años de experiencia en finanzas y mercados de capitales al consejo. Actualmente, se desempeña como CEO de Dotz Nano y es miembro del consejo de MediWound, donde anteriormente ocupó los cargos de CFO y CEO.
El Dr. Zaki Rakib, Presidente del Consejo y Presidente de la División de Servicios CDMO de BioHarvest Sciences, destacó la experiencia operativa de Malka en el avance de tecnologías innovadoras y en la estructuración de transacciones estratégicas como activos valiosos para el crecimiento de la empresa. Malka, CPA certificado con un MBA y educación ejecutiva de la Harvard Business School, expresó su entusiasmo por contribuir al desarrollo de soluciones terapéuticas basadas en la ciencia de BioHarvest, utilizando su tecnología de Síntesis Botánica.
BioHarvest Sciences (NASDAQ: BHST)가 샤론 말카를 독립 이사로 임명했습니다. 이는 즉시 효력을 발휘합니다. 말카는 25년 이상의 금융 및 자본 시장 경험을 이사회에 가져옵니다. 현재 그는 Dotz Nano의 CEO로 재직 중이며, 이전에는 CFO 및 CEO로 재직한 MediWound의 이사회에도 있습니다.
BioHarvest Sciences의 CDMO 서비스 부문 위원장인 자키 라키브 박사는 혁신적인 기술을 발전시키고 전략적 거래를 구조화하는 말카의 Operational 경험이 회사 성장에 귀중한 자산이 될 것이라고 강조했습니다. 말카는 CPA 자격증을 보유하고 있으며, MBA와 하버드 경영대학원 Executive 교육 이수 후 BioHarvest의 식물 합성 기술을 사용하여 과학 기반의 치료 솔루션 개발에 기여할 수 있기를 기대하고 있다고 밝혔습니다.
BioHarvest Sciences (NASDAQ: BHST) a nommé Sharon Malka comme administrateur indépendant, avec effet immédiat. Malka apporte au conseil plus de 25 ans d'expérience dans le secteur financier et des marchés de capitaux. Il est actuellement PDG de Dotz Nano et membre du conseil d'administration de MediWound, où il a précédemment occupé les postes de CFO et de CEO.
Dr. Zaki Rakib, Président du Conseil et Président de la Division des Services CDMO de BioHarvest Sciences, a souligné que l'expérience opérationnelle de Malka dans l'avancement des technologies innovantes et la structuration de transactions stratégiques sont des atouts précieux pour la croissance de l'entreprise. Malka, CPA certifié avec un MBA et une formation exécutive à la Harvard Business School, a exprimé son enthousiasme à contribuer au développement de solutions thérapeutiques basées sur la science par BioHarvest, en utilisant sa technologie de Synthèse Botanique.
BioHarvest Sciences (NASDAQ: BHST) hat Sharon Malka mit sofortiger Wirkung zum unabhängigen Direktor ernannt. Malka bringt über 25 Jahre Erfahrung in der Finanz- und Kapitalmarktbranche in den Vorstand ein. Er ist derzeit CEO von Dotz Nano und Mitglied des Vorstands von MediWound, wo er zuvor die Positionen des CFO und CEO innehatte.
Dr. Zaki Rakib, Vorsitzender des Vorstands und Präsident der CDMO Services Division von BioHarvest Sciences, hob Malka's operative Erfahrung in der Förderung innovativer Technologien und der Strukturierung strategischer Transaktionen als wertvolle Vermögenswerte für das Unternehmenswachstum hervor. Malka, ein zertifizierter CPA mit einem MBA und einer Ausbildung an der Harvard Business School, äußerte seine Begeisterung für die Mitwirkung an der Entwicklung wissenschaftlich fundierter therapeutischer Lösungen von BioHarvest mit Hilfe seiner Botanischen Synthesetechnologie.
- Addition of experienced board member with extensive capital markets and healthcare industry expertise
- Strategic appointment during company's growth and expansion phase
- New director brings specific experience in structuring strategic transactions and major financing rounds
- None.
Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the Board
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately.
"We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division. "His operational experience in advancing innovative technologies, and in structuring strategic transactions and major financing rounds, will be invaluable to BioHarvest in our current and future growth stages."
Sharon Malka
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/238061_a1207bd8b47a5ab9_001full.jpg
Sharon Malka, stated: "I am delighted to join BioHarvest as an independent director and am impressed with the Company's commitment to develop the next generation of science-based and clinically proven therapeutic solutions. With its leading-edge Botanical Synthesis technology, BioHarvest is poised for significant growth, and I am keen to contribute my experience and knowledge to support BioHarvest in its future success."
"Sharon is a veteran capital markets and technology executive, whose perspective and experience will be very valuable as we scale our Botanical Synthesis technology and expand our operations," commented CEO Ilan Sobel. "We are very pleased to have Sharon join our Board during this transformative phase of the company's growth."
Mr. Sharon Malka Detailed Biography
Sharon Malka brings a wealth of experience to BioHarvest, having held senior leadership positions with a number of international healthcare and technology companies. He is currently Chief Executive Officer of Dotz Nano Ltd., an Australian-based technology company focused on developing, manufacturing and commercializing advanced materials for diagnostics solutions. Mr. Sharon is currently on the Board of Directors of MediWound Limited, a Nasdaq-listed biopharmaceutical company, where he also previously served as both Chief Financial Officer and Chief Executive Officer. Prior to Mediwound, Sharon held the role of Partner at Variance Economic Consulting Ltd., a financial services consulting boutique focused on international technology company.
Mr. Malka is a certified CPA and graduate of the Executive Education Program of Harvard Business School. He holds a B.Sc. in Business Administration and an M.B.A.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond the Company's control. Readers should not place undue reliance on forward-looking statements. The Company does not intend to update forward-looking statement disclosures other than through the Company's management discussion and analysis disclosures available on the Company's profile on SEDAR+ at sedarplus.ca.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238061
FAQ
Who is the new board director appointed to BioHarvest (BHST) and what experience does he bring?
What is Sharon Malka's role at BioHarvest (BHST) and when does it take effect?
How will Sharon Malka's appointment benefit BioHarvest (BHST)?
What are Sharon Malka's current positions besides BioHarvest (BHST)?
